For decades, East Asia's biotechnology sector thrived on open collaboration across borders. Research institutions in Tokyo, Seoul, Singapore, and Shanghai shared datasets, ran joint clinical trials, and licensed technologies freely. That era is ending. The US-China technology rivalry has now opened a new front in biotechnology, and governments across the region are responding by tightening controls and building domestic capacity. The result, however, may be a slower, more fragmented innovation ecosystem.
A turning point came in January 2025, when Washington restricted China's access to advanced biotechnology equipment, including high-parameter flow cytometers and mass spectrometry systems critical for drug development and biological data analysis. These measures were followed by a bipartisan bill introduced in the US Congress in June 2026 that would extend outbound investment screening under the COINS Act to biotechnology, targeting licensing deals and research partnerships with Chinese firms. Parallel proposals have signaled interest in limiting the use of clinical trial data generated in China.
Across East Asia, governments are now racing to reduce dependence on foreign technologies. South Korea's Ministry of Science and ICT has increased funding for domestic biomanufacturing and diagnostic equipment. Japan's Ministry of Economy, Trade and Industry is promoting a 'Bio-Community Japan' initiative to strengthen domestic supply chains for reagents and lab instruments. China, under President Xi Jinping, has made biotech self-reliance a pillar of its 14th Five-Year Plan, pouring state funds into domestic sequencing platforms and gene-editing tools.
The Cost of Fragmentation
These policies carry costs that policymakers often underestimate. Unlike traditional manufacturing, biotechnology relies on cross-border collaboration between research institutions, access to diverse patient populations for clinical trials, and shared datasets used in drug discovery. Breakthroughs in genomics and advanced therapies have been driven by shared datasets and continuous cross-border collaboration. As clinical trials and research partnerships become segmented by country, innovation slows even if domestic capacity continues to expand.
Consider the case of a biotech startup in Bengaluru developing a novel cancer therapy. It might rely on genomic data from a Japanese biobank, run preclinical tests at a contract research organization in Shanghai, and conduct Phase I trials in Singapore. Under the new restrictions, each of those steps becomes more difficult. Licensing deals with Chinese firms now face US scrutiny; sharing patient data across borders raises regulatory hurdles; and equipment imports from the US are subject to export controls.
East Asia is not simply becoming more self-reliant. It is moving toward a more segmented system that could ultimately erode its long-term competitiveness. The region's biotech hubs—from Tokyo's Tsukuba Science City to Singapore's Biopolis—were built on the free flow of talent, capital, and data. That model is now under strain.
For decades, the biopharmaceutical industry operated on an efficiency-driven model that reinforced this interdependence. Companies distributed trials and manufacturing across jurisdictions based on expertise and cost. This model created deep cross-border dependencies that now sit uneasily within a more fractured geopolitical environment. The push for autonomy, while understandable, risks undoing the very networks that made East Asia one of the most dynamic centers of biotech innovation.
The broader context is a region increasingly defined by strategic competition. As China's hypersonic missile ambitions and Japan's push for rare earth price floors show, technology is now a battleground. Biotechnology is no exception. But unlike semiconductors or rare earths, biotech's success depends on collaboration across borders. Policymakers in Beijing, Tokyo, Seoul, and New Delhi must weigh the benefits of autonomy against the risk of slowing the next generation of medical breakthroughs.
